LY2963016

insulin glargine · Eli Lilly and Company

Drug timelines are a Plus or Pro feature.

9 regulatory and trial events tracked for LY2963016, covering 2014-10-07 to 2021-08-24. Get the full timeline:

Most recent: Clinical Trial Update: A Study of A Novel Approach to Titrate Basal Insulin (LY2963016) in Participants With Type 2 Diabetes [Phase 4]